SANAD Arm A: Efficacy of Newer Antiepileptic Drugs Including Lamotrigine vs. Carbamazepine in Patients with Partial Onset Seizures

calendar
24 Oct, 16

Introduction

Carbamazepine is the first-line antiepileptic drug that is used widely in patients with partial onset seizures. Several newer antiepileptic drugs are available for the treatment of this seizure type. Nevertheless, none of the existing randomized trials have speculated the choice between these newer drugs.

Aim

To compare the efficacy of various newer antiepileptic agents with regards to longer-term outcomes, quality of life, and health economic outcomes as against carbamazepine.

Patient Profile

  • Patients with a history of two or more clinically definite unprovoked epileptic seizures in the previous year for whom carbamazepine was deemed as standard treatment (n=1721)
  • Patients from Arm A of SANAD (Standard and New Antiepileptic Drugs) trial
  • 88% of the study population had cryptogenic or symptomatic partial epilepsy and 10% of them were categorized as having unclassified epilepsy

Methods

Study Design 

  • Unblinded, randomized controlled trial

Treatment Strategy

  • Patients were randomized 1:1:1:1 to one of the following drugs

Primary Outcome

  • Time to treatment failure
  • Time to 12-months remission of seizures

Secondary Outcome

  • Time from randomization to a first seizure
  • Time to achieve a 2-year remission
  • The incidence of clinically important adverse events (AEs)
  • Quality of life outcomes and cost-effectiveness of the different drugs

Results

  • Of the 71 deaths reported during the study period, 10 were attributed to epilepsy (including accidental deaths caused by seizures, status epilepticus, and all sudden deaths). Of these, 1 was attributed to carbamazepine, 2 to gabapentin, 4 to lamotrigine, 3 to oxcarbazepine, and none to topiramate
  • The treatment failure rates were the least with lamotrigine. In fact, lamotrigine was significantly better than carbamazepine, gabapentin and topiramate and non-significantly better than oxcarbazepine (Table 1).
Table 1: Treatment failure rate with the study medications

 

Baseline Drug

 

Carbamazepine

Gabapentin

Lamotrigine

Topiramate

Gabapentin

1.21

-

-

-

Lamotrigine

0.78

0.65

-

-

Topiramate

1.22

1.01

1.56

-

Oxcarbazepine

1.04

0.75

1.15

0.90

  • Time to 12-month remission was significantly better with carbamazepine vs. all the other medications. Nevertheless, the advantage of carbamazepine over lamotrigine was non-significant
  •  The rate of treatment failure due to adverse effects as well as due to inadequate seizure control was significantly better with lamotrigine (Table 2).
Table 2: Rate of treatment failure in the study groups

 

Year 1

Year 2

Year 3

Year 4

Year 5

Year 6

Unacceptable AEs

Percentage without failure

Carbamazepine

74

70

69

69

68

68

Difference in percentage without failure vs. carbamazepine

Gabapentin

9

11

11

11

12

12

Lamotrigine

10

11

10

11

10

10

Topiramate

0

0

-1

0

1

-2

Oxcarbazepine *

3

4

4

5

-

-

*Patients were randomized to oxcarbazepine almost 2 years after the first randomization

Inadequate seizure control

Percentage without failure

Carbamazepine

92

87

84

82

77

73

Differences in percentage without failure vs. carbamazepine

Gabapentin

-17

-19

-21

-21

-18

15

Lamotrigine

0

-2

-4

-6

-3

1

Topiramate

-4

-8

-7

-7

-5

-2

Oxcarbazepine

-4

-4

-4

-6

-

-

*Patients were randomized to oxcarbazepine almost 2 years after the first randomization

  • The proportion of patients achieving a 12-month remission (lamotrigine-carbamazepine) at 2 and 4 years was 0 and 5, indicating non-inferiority of lamotrigine vs. carbamazepine.

Conclusions

  • Amongst patients with partial onset seizure requiring monotherapy, lamotrigine was clinically better than carbamazepine (the standard drug treatment) and other newer antiepileptic agents (gabapentin and topiramate), in terms of  time to treatment failure 
  • Lamotrigine was non-inferior to carbamazepine for time to 12-month remission from seizure
  • Lamotrigine thus offers a cost-effective alternative for patients diagnosed with partial onset seizures

Lancet. 2007; 369: 1000–15